AEON Biopharma Warrants, each whole warrant exercisable to purchase one share of Stock Price, News & Analysis

AEON Biopharma, Inc. (NYSE: AEON, AEON.WS) is a clinical-stage biopharmaceutical company that focuses on developing therapeutic botulinum toxin complexes for treating various debilitating medical conditions. The company's core product, ABP-450 (prabotulinumtoxinA), is designed to address conditions such as chronic and episodic migraine, cervical dystonia, and gastroparesis. ABP-450 is the same botulinum toxin complex marketed under the name Jeuveau for cosmetic indications by Evolus.

Recently, AEON completed a business combination with Priveterra Acquisition Corp., securing a listing on the New York Stock Exchange American. This merger, along with $50 million in committed financing, ensures that AEON has sufficient funds to continue its groundbreaking clinical trials. The company plans to announce topline data from its Phase 2 study on episodic migraine by fall 2023 and from its chronic migraine study in 2024.

AEON’s experienced management team, led by CEO Marc Forth and Chairman Jost Fischer, is confident that the ongoing and future clinical milestones will significantly impact the medical field. The company has also cleared an Investigational New Drug (IND) application with the FDA for a Phase 2 study of ABP-450 to treat gastroparesis and is conducting preclinical studies for posttraumatic stress disorder (PTSD).

With exclusive development and distribution rights for ABP-450 in the U.S., Canada, the EU, the UK, and other international territories, AEON is well-positioned to leverage its advanced therapeutic neurotoxin capabilities. For more detailed updates and information, visit their official website at aeonbiopharma.com.